Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, ...
AP2A1 could serve as a biomarker for aging and a target for therapies aimed at slowing down or even reversing the aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback